Associated Papers
Germline EGFR T790M in Lung Cancer: Prevalence, Clinical Impact, and Implications for Hereditary Risk.
Melikova LA et al.
Cancer Prevention Research (philadelphia, Pa.), 2025
Germline EGFR T790M in Lung Cancer: Prevalence, Clinical Impact, and Implications for Hereditary Risk.
Melikova LA et al.
Cancer Prevention Research (philadelphia, Pa.), 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Clinical Outcomes of Later-Generation EGFR-TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real-World Study.
Shigematsu L et al.
Thoracic Cancer, 2025
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review.
Abujamous L et al.
The Oncologist, 2025
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.
Yu Y et al.
Bmc Pulmonary Medicine, 2025
Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.
Castañeda-González JP et al.
Clinical Lung Cancer, 2025
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.
Vadagam P et al.
Current Oncology (toronto, Ont.), 2025
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma.
Pomares AA et al.
Plos One, 2025
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients.
Ali MA et al.
Ejnmmi Reports, 2024
Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.
Burr R et al.
Nature Cancer, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Vasseur D et al.
Molecular Cancer, 2024
Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer.
Lillesand M et al.
Diagnostics (basel, Switzerland), 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations.
Li Y et al.
Hereditary Cancer in Clinical Practice, 2024
Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis.
Attili I et al.
Journal of Clinical Medicine, 2024
A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review.
Sharma P et al.
Clinical Lung Cancer, 2024
Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.
Huang CY et al.
Cancer Research, 2024
Single nucleotide variants in lung cancer.
Tian X et al.
Chinese Medical Journal Pulmonary and Critical Care Medicine, 2024
Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing.
Yu Z et al.
Molecular Oncology, 2024
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer.
Bai H et al.
Heliyon, 2024
Lung cancer in patients who have never smoked - an emerging disease.
LoPiccolo J et al.
Nature Reviews. Clinical Oncology, 2024
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Tóth LJ et al.
Pathology Oncology Research : Por, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer.
Burr R et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
Farinea G et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2023
Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies.
Aktas T et al.
Frontiers in Bioscience (landmark Edition), 2023
Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family.
Xiao N et al.
Journal of Cancer Research and Clinical Oncology, 2023
Germline EGFR c.2527G > A (p.V843I) variant and familial lung cancer.
Alsaddah S et al.
Lung Cancer (amsterdam, Netherlands), 2023
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays.
Barthelemy D et al.
Cancers, 2023
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules.
Wu Z et al.
Journal of Cancer Research and Clinical Oncology, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review.
Li D et al.
Oncotargets and Therapy, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS.
Vogelaar IP et al.
Cancers, 2022
Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
Trabelsi Grati O et al.
Lung Cancer (amsterdam, Netherlands), 2022
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group.
Toss A et al.
Current Oncology Reports, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y et al.
Annals of Palliative Medicine, 2022
Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer.
Li N et al.
Annals of Translational Medicine, 2022
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
Lim SM et al.
Therapeutic Advances in Medical Oncology, 2022
Integrated spatial analysis of gene mutation and gene expression for understanding tumor diversity in formalin-fixed paraffin-embedded lung adenocarcinoma.
Yamazaki M et al.
Frontiers in Oncology, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Lung cancer is also a hereditary disease.
Benusiglio PR et al.
European Respiratory Review : an Official Journal of the European Respiratory Society, 2021